DSGN
Design Therapeutics, Inc.
There isn't enough reported data to score DSGN yet.
DSGN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
DSGN's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
DSGN PE Valuation
DSGN has no meaningful PE right now: it lost money over the past year.
DSGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect DSGN's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
DSGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.20 | -$0.01 |
| Q2 2026 | -$1.18 | -$0.06 |
| Q1 2026 | -$1.20 | -$0.21 |
| Q4 2025 | -$1.22 | -$0.34 |
| Q3 2025 | -$1.19 | -$0.35 |
| Q2 2025 | -$1.12 | -$0.23 |
| Q1 2025 | -$0.99 | +$0.05 |
| Q4 2024 | -$0.88 | +$0.31 |
DSGN lost $1.20 per share over the past year, about the same as its loss the year before.
DSGN Quarterly Revenue
DSGN's revenue is shrinking: $0 last quarter.
DSGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.4M | -$4.2M |
| Q2 2026 | -$15.5M | -$1M |
| Q1 2026 | -$16.4M | +$430K |
| Q4 2025 | -$12M | -$2.1M |
| Q3 2025 | -$11.2M | -$1.6M |
| Q2 2025 | -$14.5M | -$3.1M |
| Q1 2025 | -$16.9M | -$4.2M |
| Q4 2024 | -$9.9M | +$3M |
DSGN has burned cash in almost every quarter: −$59M over the past year, against −$52M the year before.
DSGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +530K shares |
| 1 year | +11% | +6.1M shares |
| 3 years | +13% | +7M shares |
| 5 years | +14% | +7.9M shares |
| Available history | +132% | +35.8M shares |
DSGN has 63M diluted shares, up 11% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
DSGN Net Leverage
DSGN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
DSGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.4 | Neutral |
| Stochastic | 15.3 | Oversold |
DSGN's weekly RSI is 42 (neutral) and its Stochastic is 15 (oversold).
DSGN PE vs Healthcare Sector
DSGN has no meaningful PE right now: it lost money over the past year.
DSGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.0 | 4% below |
| 20 week MA | $12.8 | 17% below |
| 50 week MA | $11.7 | 9.6% below |
| 100 week MA | $8.37 | 26% above |
| 200 week MA | $6.47 | 64% above |
DSGN has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 64% above its 200-week average.
DSGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $41.5 | $18.4 | -56% |
| 2022 | $18.4 | $9.53 | -48% |
| 2023 | $9.53 | $2.65 | -72% |
| 2024 | $2.65 | $6.25 | +136% |
| 2025 | $6.25 | $9.63 | +54% |
| 2026 YTD | $9.63 | $10.6 | +9.9% |
DSGN's yearly returns have swung widely, from +136% in 2024 to −72% in 2023. It's up 9.9% so far in 2026.